These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19225428)

  • 1. Relationship between circulating tumor necrosis factor system and bone mass before and after estrogen plus progestogen therapy.
    Kim JG; Ku SY; Kim H; Chun SW; Suh CS; Choi YM
    Menopause; 2009; 16(3):534-8. PubMed ID: 19225428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between polymorphisms in tumor necrosis factor (TNF) and TNF receptor genes and circulating TNF, soluble TNF receptor levels, and bone mineral density in postmenopausal Korean women.
    Kim H; Chun S; Ku SY; Suh CS; Choi YM; Kim JG
    Menopause; 2009; 16(5):1014-20. PubMed ID: 19369902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
    Svenungsson E; Gunnarsson I; Fei GZ; Lundberg IE; Klareskog L; Frostegård J
    Arthritis Rheum; 2003 Sep; 48(9):2533-40. PubMed ID: 13130473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between Wnt signaling pathway gene polymorphisms and bone response to hormone therapy in postmenopausal Korean women.
    Kim H; Choe SA; Ku SY; Kim SH; Kim JG
    Menopause; 2011 Jul; 18(7):808-13. PubMed ID: 21471826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy.
    Gür A; Denli A; Nas K; Cevik R; Karakoc M; Sarac AJ; Erdogan F
    Rheumatol Int; 2002 Sep; 22(5):194-8. PubMed ID: 12215865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the calcitonin gene (CA) polymorphism with bone mass and bone responsiveness to hormone therapy in postmenopausal Korean women.
    Kim JG; Choi YM; Moon SY; Lee JY
    Menopause; 2003; 10(6):544-9. PubMed ID: 14627864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3.
    Tziakas D; Chalikias G; Parissis JT; Hatzinikolaou H; Stakos D; Papadopoulou E; Kortsaris A; Hatseras D
    Eur Cytokine Netw; 2004; 15(3):231-9. PubMed ID: 15542448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K; Gossec L; Kolta S; Dougados M; Roux C
    J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type D personality is associated with increased levels of tumour necrosis factor (TNF)-alpha and TNF-alpha receptors in chronic heart failure.
    Conraads VM; Denollet J; De Clerck LS; Stevens WJ; Bridts C; Vrints CJ
    Int J Cardiol; 2006 Oct; 113(1):34-8. PubMed ID: 16325284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between estrogens and serum adipocytokines in premenopausal and postmenopausal women.
    Hong SC; Yoo SW; Cho GJ; Kim T; Hur JY; Park YK; Lee KW; Kim SH
    Menopause; 2007; 14(5):835-40. PubMed ID: 17667144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum levels of solubule tumor necrosis factor (TNF) receptors in patients with pulmonary tuberculosis].
    Kawaguchi H; Ina Y; Ito S; Sato S; Sugiura Y; Tomita H; Ogisu N; Takada K; Yamamoto M; Morishita M; Yoshikawa K
    Kekkaku; 1996 Mar; 71(3):259-65. PubMed ID: 8901228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal evaluation of serum leptin and bone mineral density in early postmenopausal women.
    Di Carlo C; Tommaselli GA; Di Spiezio Sardo A; Sammartino A; Attianese W; Gargano V; Bifulco G; Nappi C
    Menopause; 2007; 14(3 Pt 1):450-4. PubMed ID: 17242633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy.
    Song EK; Yeom JH; Shin HT; Kim SH; Shin WG; Oh JM
    J Clin Pharm Ther; 2006 Oct; 31(5):421-7. PubMed ID: 16958819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in profiles of circulating insulin-like growth factor components during hormone replacement therapy according to the responsiveness to therapy in postmenopausal women.
    Kim JG; Lee JY
    Am J Obstet Gynecol; 2001 May; 184(6):1139-44. PubMed ID: 11349179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor necrosis factor alpha is higher in non-obese, non-diabetic Mexican Americans compared to non-Hispanic white adults.
    Ho RC; Davy KP; Hickey MS; Melby CL
    Cytokine; 2005 Apr; 30(1):14-21. PubMed ID: 15784408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.